Detail akcie Vanda Pharma online

Business Summary: Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Vanda Pharmaceuticals Inc. revenues decreased less than 1% to $102.2M. Net loss increased 96% to $111.1M. Revenues reflect Fanapt segment increase of 24% to $65.5M, PONVORY segment increase of 11% to $14.1M, also reflect Hetlioz segment decrease of 42% to $21.5M. Higher net loss reflects Selling, General and administrative - increase of 23% to $136.7M (expense).